Regimen received and treatment outcomes among patients on standard and prolonged treatment with bedaquiline
| Bedaquiline <190 days | Bedaquiline >190 days | p-value# | |||
| Patients n | 83 | 30 | |||
| Regimen duration | |||||
| Median (IQR) total treatment duration, months | 23.7 (20.7–24.0) | 24.2 (23.8–24.9) | <0.01 | ||
| Median (IQR) treatment duration with bedaquiline, months | 5.5 (5.4–5.6) | 8.0 (7.3–9.2) | <0.01 | ||
| Median (IQR) treatment duration with linezolid, months¶ | 23.5 (20.1–24.0) | 24.1 (23.7–24.4) | <0.01 | ||
| Median (IQR) treatment duration with injectables, months+ | 5.3 (5.3–21.2) | 13.8 (10.7–24.2) | 0.02 | ||
| Treatment outcomes | |||||
| Number with treatment success | 77 (92.8) | 29 (96.7) | 0.75 | ||
| Number with failure | 1 (1.2) | 0 (0) | 1 | ||
| Number dying during treatment | 3 (3.6) | 1 (3.3) | 1 | ||
| Number lost to follow-up | 2 (2.4) | 0 (0) | 0.96 | ||
| Regimen received | Initial | Added during treatment | Initial | Added during treatment | |
| Number of drugs in initial regimen, median (IQR) | 6 (5–6) | – | 6 (6–6) | – | 0.80 |
| Included moxifloxacin or levofloxacin or gatifloxacin | 11 (13.3) | 43 (51.8) | 0 (0) | 15 (50) | 0.08 |
| Included linezolid | 83 (100) | 0 (0) | 29 (96.7) | 1 (3.3) | 0.59 |
| Included clofazimine | 80 (96.4) | 1 (1.2) | 27 (90) | 2 (6.7) | 0.39 |
| Included terizidone | 82 (98.8) | 0 (0) | 28 (93.3) | 2 (6.7) | 0.35 |
| Included amikacin or capreomycin or kanamycin | 32 (38.6) | 6 (7.2) | 14 (46.7) | 10 (33.3) | 0.58 |
| Included pyrazinamide | 54 (65.1) | 2 (2.4) | 23 (76.7) | 0 (0) | 0.35 |
| Included imipenem/cilastatin with amoxicillin and clavulanic acid | 42 (50.6) | 2 (2.4) | 16 (53.3) | 7 (23.3) | 0.97 |
| Included ethionamide or prothionamide | 8 (9.6) | 8 (9.6) | 2 (6.7) | 3 (10) | 0.91 |
Data reported as n (%) unless otherwise specified. #: the following tests were used to calculate p-value: for medians Kruskal–Wallis test; for proportions Chi square test; for rates exact Fisher two-sided test. For the regimen received, p-value only refers to initial regimen. ¶: all patients received linezolid during treatment. +: only if received injectables ever during treatment (n=35 bedaquiline 6 months; n=20 bedaquiline >6 months; n=55 overall).